Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease

Background: Pulmonary hypertension due to interstitial lung disease (ILD-PH) portends very poor clinical outcomes, with a median survival time of 1.5 to 2 years. Currently, there is no tool to assess the risk of clinical worsening in patients with ILD-PH. Our aim was to derive a simple and practical...

Full description

Saved in:
Bibliographic Details
Main Authors: K. El-Kersh, R. Bag, N. Bhatt, C. King, A. Waxman, F. Rischard, H. Kim, D. Cella, E. Shen, SD Nathan
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:JHLT Open
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2950133425000011
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823864121954664448
author K. El-Kersh
R. Bag
N. Bhatt
C. King
A. Waxman
F. Rischard
H. Kim
D. Cella
E. Shen
SD Nathan
author_facet K. El-Kersh
R. Bag
N. Bhatt
C. King
A. Waxman
F. Rischard
H. Kim
D. Cella
E. Shen
SD Nathan
author_sort K. El-Kersh
collection DOAJ
description Background: Pulmonary hypertension due to interstitial lung disease (ILD-PH) portends very poor clinical outcomes, with a median survival time of 1.5 to 2 years. Currently, there is no tool to assess the risk of clinical worsening in patients with ILD-PH. Our aim was to derive a simple and practical risk calculator that could be used to predict risk of clinical worsening in patients with ILD-PH. Methods: The INCREASE study was a 16-week study that evaluated inhaled treprostinil in patients with ILD-PH. Baseline data from patients who were randomized to the placebo arm (n=163) and thus untreated with any approved pulmonary artery vasodilators were used to derive a risk calculator. The endpoint of interest was the time to clinical worsening. Stepwise regression, Harrell’s c-index, and clinician input were used to derive 2 multivariable Cox PH models from a set of candidate variables. The models were then simplified by applying a point-scoring system to the predictors and refitting with total point score as the covariate. Total point scores were grouped into 3 risk strata (lower, intermediate, and higher). Results: Two versions of a risk calculator were derived. The first was a non-invasive risk calculator which included NT-proBNP and FVC%/DLCO%, and a second adds cardiac index, an invasive parameter, to the above two parameters. For the total point score models, the estimated c-indices were 0.703 (95% CI: 0.635, 0.783) and 0.683 (95% CI: 0.612, 0.761) for the invasive and non-invasive model, respectively. Conclusion: These two risk calculators provide a simple way to risk stratify ILD-PH patients with clinically useful discrimination. The calculators are easy to employ in clinical practice, since they utilize assessments commonly collected in the care of patients with ILD-PH. Moreover, the calculators can provide clinicians with important prognostic information which can be used to reinforce the benefits of therapy. The risk calculators may also find utility as part of the composite allocation score of ILD-PH patients listed for lung transplant. Future research in this area could include incorporating longer-term outcomes as well as validating the risk models in a separate patient population.
format Article
id doaj-art-d953e5a3da8c4bf48e5a1fb1b9d0fc95
institution Kabale University
issn 2950-1334
language English
publishDate 2025-02-01
publisher Elsevier
record_format Article
series JHLT Open
spelling doaj-art-d953e5a3da8c4bf48e5a1fb1b9d0fc952025-02-09T05:02:02ZengElsevierJHLT Open2950-13342025-02-017100206Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung diseaseK. El-Kersh0R. Bag1N. Bhatt2C. King3A. Waxman4F. Rischard5H. Kim6D. Cella7E. Shen8SD Nathan9University of Arizona College of Medicine, PhoenixMayo ClinicThe Ohio State University Medical CenterInova Fairfax HospitalBrigham and Women’s HospitalUniversity of Arizona College of Medicine, TucsonNorth Carolina State UniversityUnited Therapeutics CorporationUnited Therapeutics CorporationInova Fairfax Hospital; Reprint requests: Steven D. Nathan, Inova Fairfax Hospital, Advanced Lung Disease and Transplant Program, 3300 Gallows Road, Falls Church, VA 22042.Background: Pulmonary hypertension due to interstitial lung disease (ILD-PH) portends very poor clinical outcomes, with a median survival time of 1.5 to 2 years. Currently, there is no tool to assess the risk of clinical worsening in patients with ILD-PH. Our aim was to derive a simple and practical risk calculator that could be used to predict risk of clinical worsening in patients with ILD-PH. Methods: The INCREASE study was a 16-week study that evaluated inhaled treprostinil in patients with ILD-PH. Baseline data from patients who were randomized to the placebo arm (n=163) and thus untreated with any approved pulmonary artery vasodilators were used to derive a risk calculator. The endpoint of interest was the time to clinical worsening. Stepwise regression, Harrell’s c-index, and clinician input were used to derive 2 multivariable Cox PH models from a set of candidate variables. The models were then simplified by applying a point-scoring system to the predictors and refitting with total point score as the covariate. Total point scores were grouped into 3 risk strata (lower, intermediate, and higher). Results: Two versions of a risk calculator were derived. The first was a non-invasive risk calculator which included NT-proBNP and FVC%/DLCO%, and a second adds cardiac index, an invasive parameter, to the above two parameters. For the total point score models, the estimated c-indices were 0.703 (95% CI: 0.635, 0.783) and 0.683 (95% CI: 0.612, 0.761) for the invasive and non-invasive model, respectively. Conclusion: These two risk calculators provide a simple way to risk stratify ILD-PH patients with clinically useful discrimination. The calculators are easy to employ in clinical practice, since they utilize assessments commonly collected in the care of patients with ILD-PH. Moreover, the calculators can provide clinicians with important prognostic information which can be used to reinforce the benefits of therapy. The risk calculators may also find utility as part of the composite allocation score of ILD-PH patients listed for lung transplant. Future research in this area could include incorporating longer-term outcomes as well as validating the risk models in a separate patient population.http://www.sciencedirect.com/science/article/pii/S2950133425000011Pulmonary hypertensionInterstitial lung diseaseRisk assessment
spellingShingle K. El-Kersh
R. Bag
N. Bhatt
C. King
A. Waxman
F. Rischard
H. Kim
D. Cella
E. Shen
SD Nathan
Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease
JHLT Open
Pulmonary hypertension
Interstitial lung disease
Risk assessment
title Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease
title_full Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease
title_fullStr Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease
title_full_unstemmed Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease
title_short Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease
title_sort derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease
topic Pulmonary hypertension
Interstitial lung disease
Risk assessment
url http://www.sciencedirect.com/science/article/pii/S2950133425000011
work_keys_str_mv AT kelkersh derivationofasimpleriskcalculatorforpredictingclinicalworseninginpatientswithpulmonaryhypertensionduetointerstitiallungdisease
AT rbag derivationofasimpleriskcalculatorforpredictingclinicalworseninginpatientswithpulmonaryhypertensionduetointerstitiallungdisease
AT nbhatt derivationofasimpleriskcalculatorforpredictingclinicalworseninginpatientswithpulmonaryhypertensionduetointerstitiallungdisease
AT cking derivationofasimpleriskcalculatorforpredictingclinicalworseninginpatientswithpulmonaryhypertensionduetointerstitiallungdisease
AT awaxman derivationofasimpleriskcalculatorforpredictingclinicalworseninginpatientswithpulmonaryhypertensionduetointerstitiallungdisease
AT frischard derivationofasimpleriskcalculatorforpredictingclinicalworseninginpatientswithpulmonaryhypertensionduetointerstitiallungdisease
AT hkim derivationofasimpleriskcalculatorforpredictingclinicalworseninginpatientswithpulmonaryhypertensionduetointerstitiallungdisease
AT dcella derivationofasimpleriskcalculatorforpredictingclinicalworseninginpatientswithpulmonaryhypertensionduetointerstitiallungdisease
AT eshen derivationofasimpleriskcalculatorforpredictingclinicalworseninginpatientswithpulmonaryhypertensionduetointerstitiallungdisease
AT sdnathan derivationofasimpleriskcalculatorforpredictingclinicalworseninginpatientswithpulmonaryhypertensionduetointerstitiallungdisease